Literature DB >> 12598305

Persistent localization of activated extracellular signal-regulated kinases (ERK1/2) is epithelial cell-specific in an inhalation model of asbestosis.

Andrew B Cummins1, Cathy Palmer, Brooke T Mossman, Douglas J Taatjes.   

Abstract

Asbestos fibers up-regulate the extracellular signal-regulated kinase (ERK1/2) pathway in mesothelial and pulmonary epithelial cells in vitro, but the cell-type expression patterns and intracellular localization of activated, ie, phosphorylated, ERK in the lung after inhalation of asbestos are unclear. C57/BL6 mice were exposed to 7-mg/m(3) air of crocidolite asbestos for 5 and 30 days, the times required for the development of epithelial cell hyperplasia and fibrotic lesions, respectively. Exposure to asbestos caused striking increases in both unphosphorylated and phosphorylated ERK (p-ERK), which were most marked at 30 days and co-localized in bronchiolar and alveolar epithelial cells using an antibody to cytokeratin. Alveolar macrophages, detected with an anti-macrophage antibody, did not express p-ERK. p-ERK was localized at the apical cell surface of bronchiolar and alveolar type II epithelial cells exposed to asbestos fibers, and was most marked in areas of epithelial hyperplasia in association with fibrotic lesions. Because translocation of p-ERK to the nucleus is associated with activation of early response genes and transcription factors, laser scanning cytometry was used to determine the kinetics of activation and nuclear translocation of p-ERK in an alveolar type II epithelial cell line in vitro after exposure to asbestos or the ERK stimuli, epidermal growth factor, or H(2)O(2). Results showed that cytoplasmic to nuclear translocation of p-ERK occurred in a protracted manner in cells exposed to asbestos. The immunolocalization of p-ERK at the membrane surface, a site of initial exposure to asbestos fibers, and the chronic activation of p-ERK in epithelial cells at sites of fibrogenesis are consistent with the concept that epithelial cell signaling through the ERK pathway contributes to remodeling of the lung during the development of pulmonary fibrosis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12598305      PMCID: PMC1868103          DOI: 10.1016/S0002-9440(10)63867-9

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  25 in total

Review 1.  Laser-based microscopic approaches: application to cell signaling in environmental lung disease.

Authors:  D J Taatjes; C J Palmer; C Pantano; S B Hoffmann; A Cummins; B T Mossman
Journal:  Biotechniques       Date:  2001-10       Impact factor: 1.993

Review 2.  Diseases caused by asbestos: mechanisms of injury and disease development.

Authors:  Christopher B Manning; Val Vallyathan; Brooke T Mossman
Journal:  Int Immunopharmacol       Date:  2002-02       Impact factor: 4.932

Review 3.  Mechanisms in the pathogenesis of asbestosis and silicosis.

Authors:  B T Mossman; A Churg
Journal:  Am J Respir Crit Care Med       Date:  1998-05       Impact factor: 21.405

4.  Identification of a docking groove on ERK and p38 MAP kinases that regulates the specificity of docking interactions.

Authors:  T Tanoue; R Maeda; M Adachi; E Nishida
Journal:  EMBO J       Date:  2001-02-01       Impact factor: 11.598

5.  Different accumulation of activated extracellular signal-regulated kinases (ERK 1/2) and role in cell-cycle alterations by epidermal growth factor, hydrogen peroxide, or asbestos in pulmonary epithelial cells.

Authors:  S Buder-Hoffmann; C Palmer; P Vacek; D Taatjes; B Mossman
Journal:  Am J Respir Cell Mol Biol       Date:  2001-04       Impact factor: 6.914

6.  Activation of extracellular signal-regulated kinase in human prostate cancer.

Authors:  D T Price; G Della Rocca; C Guo; M S Ballo; D A Schwinn; L M Luttrell
Journal:  J Urol       Date:  1999-10       Impact factor: 7.450

7.  Increased phosphorylated extracellular signal-regulated kinase immunoreactivity associated with proliferative and morphologic lung alterations after chrysotile asbestos inhalation in mice.

Authors:  R F Robledo; S A Buder-Hoffmann; A B Cummins; E S Walsh; D J Taatjes; B T Mossman
Journal:  Am J Pathol       Date:  2000-04       Impact factor: 4.307

8.  Asbestos-induced phosphorylation of epidermal growth factor receptor is linked to c-fos and apoptosis.

Authors:  C L Zanella; C R Timblin; A Cummins; M Jung; J Goldberg; R Raabe; T R Tritton; B T Mossman
Journal:  Am J Physiol       Date:  1999-10

9.  Translocation of MAP (Erk-1 and -2) kinases to cell nuclei and activation of c-fos gene during healing of experimental gastric ulcers.

Authors:  A S Tarnawski; R Pai; H Wang; M Tomikawa
Journal:  J Physiol Pharmacol       Date:  1998-12       Impact factor: 3.011

10.  Activation of nuclear factor kappa B (NF-kappaB) assayed by laser scanning cytometry (LSC).

Authors:  A Deptala; E Bedner; W Gorczyca; Z Darzynkiewicz
Journal:  Cytometry       Date:  1998-11-01
View more
  12 in total

1.  Decreased asbestos-induced lung inflammation and fibrosis after radiation and bone marrow transplant.

Authors:  Jamie Levis; Roberto Loi; Kelly J Butnor; Pamela Vacek; Chad Steele; Brooke T Mossman; Daniel J Weiss
Journal:  Am J Respir Cell Mol Biol       Date:  2007-08-02       Impact factor: 6.914

2.  Epidermal growth factor receptor signaling is partially responsible for the increased matrix metalloproteinase-1 expression in ocular epithelial cells after UVB radiation.

Authors:  Nick Di Girolamo; Minas Coroneo; Denis Wakefield
Journal:  Am J Pathol       Date:  2005-08       Impact factor: 4.307

3.  ERK2 is essential for the growth of human epithelioid malignant mesotheliomas.

Authors:  Arti Shukla; Jedd M Hillegass; Maximilian B MacPherson; Stacie L Beuschel; Pamela M Vacek; Kelly J Butnor; Harvey I Pass; Michele Carbone; Joseph R Testa; Nicholas H Heintz; Brooke T Mossman
Journal:  Int J Cancer       Date:  2011-01-06       Impact factor: 7.396

4.  Modulation of prosurvival signaling in fibroblasts by a protein kinase inhibitor protects against fibrotic tissue injury.

Authors:  Ragini Vittal; Jeffrey C Horowitz; Bethany B Moore; Hengmin Zhang; Fernando J Martinez; Galen B Toews; Theodore J Standiford; Victor J Thannickal
Journal:  Am J Pathol       Date:  2005-02       Impact factor: 4.307

Review 5.  Pulmonary endpoints (lung carcinomas and asbestosis) following inhalation exposure to asbestos.

Authors:  Brooke T Mossman; Morton Lippmann; Thomas W Hesterberg; Karl T Kelsey; Aaron Barchowsky; James C Bonner
Journal:  J Toxicol Environ Health B Crit Rev       Date:  2011       Impact factor: 6.393

Review 6.  Oxidants and signaling by mitogen-activated protein kinases in lung epithelium.

Authors:  Brooke T Mossman; Karen M Lounsbury; Sekhar P Reddy
Journal:  Am J Respir Cell Mol Biol       Date:  2006-02-16       Impact factor: 6.914

Review 7.  The role of inflammation in the pathogenesis of idiopathic pulmonary fibrosis.

Authors:  Benjamin D Bringardner; Christopher P Baran; Timothy D Eubank; Clay B Marsh
Journal:  Antioxid Redox Signal       Date:  2008-02       Impact factor: 8.401

Review 8.  Asbestos, lung cancers, and mesotheliomas: from molecular approaches to targeting tumor survival pathways.

Authors:  Nicholas H Heintz; Yvonne M W Janssen-Heininger; Brooke T Mossman
Journal:  Am J Respir Cell Mol Biol       Date:  2010-02       Impact factor: 6.914

9.  Gremlin-mediated decrease in bone morphogenetic protein signaling promotes pulmonary fibrosis.

Authors:  Marjukka Myllärniemi; Pamela Lindholm; Merja J Ryynänen; Corrine R Kliment; Kaisa Salmenkivi; Jorma Keski-Oja; Vuokko L Kinnula; Tim D Oury; Katri Koli
Journal:  Am J Respir Crit Care Med       Date:  2007-11-01       Impact factor: 21.405

10.  Targeting the MEK1 cascade in lung epithelium inhibits proliferation and fibrogenesis by asbestos.

Authors:  Christopher B Manning; Tara Sabo-Attwood; Raymond F Robledo; Maximilian B Macpherson; Mercedes Rincón; Pamela Vacek; David Hemenway; Douglas J Taatjes; Patty J Lee; Brooke T Mossman
Journal:  Am J Respir Cell Mol Biol       Date:  2008-01-10       Impact factor: 6.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.